Trastuzumab v liečbe karcinómu prsníka: mechanizmy účinku a rezistencie

Warning

This publication doesn't include Faculty of Sports Studies. It includes Faculty of Medicine. Official publication website can be found on muni.cz.
Title in English Trastuzumab in the breast cancer treatment efficacy and resistance mechanisms
Authors

GRELL Peter SVOBODA Marek ŠIMÍČKOVÁ Marta FABIAN Pavel VYZULA Rostislav

Year of publication 2009
Type Article in Periodical
Magazine / Source Klinická onkologie
MU Faculty or unit

Faculty of Medicine

Citation
Web http://www.linkos.cz/odbornici/vzdelavani/2_09/01.pdf
Field Oncology and hematology
Keywords trastuzurnab;breast cancer;oncogene protein HER-2;mechanism of action;drug resistance
Description Summary Trastuzumab, a humanized monoclonal antibody against the HER-2 receptor,was the first targeted therapy for HER-2 positive breast cancer. The treatment of HER-2 positive breast cancer in monotherapy, but mainly in combination with cytostatics trastuzumab, showed signifficant efficacy and increased the time to progression/relapse and overall survival. On the other hand, despite it being administered to only a selected patient population, the response rate varies in range and duration due to the primary or acquired tumor resistance to trastuzumab. Several mechanisms contributing to the drug resistance are presumed and overcoming strategies are in development in connection with the drug resistance there are the mechanisms of trastuzumabs action on tumor cells and the search for feasible biomarkers in order to predict the response of trastuzumab-based targeted therapies. Furthermore, we present here the actual possibilities to overcome primary or acquired trastuzumab resistance.

You are running an old browser version. We recommend updating your browser to its latest version.

More info